Pharmacoepidemiology Signal Detection & Safety Analysis
Detect and characterize drug safety signals with pharmacoepi rigor
What You Can Do
You leverage pharmacoepidemiology methodology to automatically detect potential safety signals from adverse event data, perform statistical significance testing, and generate evidence-based safety characterizations. Claude analyzes disproportionality metrics, temporal trends, and risk stratification to support regulatory decision-making and clinical trial monitoring with peer-reviewed methodology.
Features
Calculate ROR (Reporting Odds Ratio), PRR (Proportional Reporting Ratio), and IC (Information Component) with confidence intervals to identify adverse events reported more frequently than expected
Apply frequentist and Bayesian methods to determine whether detected signals meet statistical thresholds for further investigation and regulatory escalation
Identify acceleration or deceleration of adverse event reporting over time, with seasonal adjustment and anomaly detection for emerging safety concerns
Segment signals by patient subgroups (age, comorbidities, concomitant medications, dose) to identify at-risk populations and refine safety characterization
Flag incomplete narratives, duplicate reports, data entry errors, and missing covariates that could bias signal detection or confound causality assessment
Organize narratives for manual causality scoring using WHO-UMC or Naranjo criteria, with automated highlighting of key temporal, dechallenge/rechallenge, and alternative cause evidence
Produce formatted safety narratives, risk-benefit summaries, and expedited reporting templates (IND safety reports, MedWatch, EudraVigilance) ready for submission
Synthesize signals across clinical trials, EHR data, insurance claims, and public adverse event databases with source-specific weighting and conflict resolution
Example Output
Signal Detection Summary (Hypothetical):
- Adverse Event: Hepatotoxicity (Standardized MedDRA Query)
- ROR (95% CI): 2.8 (2.1–3.7), statistically significant
- Number of Cases: 42 observed vs. 15 expected
- Temporal Trend: Steady reporting over 18 months; no acceleration
- High-Risk Subgroup: Patients ≥65 years old (ROR 4.2) and those on concomitant statins (ROR 3.5)
- Data Quality: 95% complete narratives; 1 duplicate flagged for deduplication
- Recommendation: Signal confirmed. Escalate to pharmacovigilance committee; consider REMS restriction for high-risk populations
Causality Assessment Narrative (Excerpt):
Case #AR-2026-0847: 68-year-old female, AST/ALT elevated 5× ULN on study day 43, improved post-dechallenge (day 58), re-elevated on rechallenge (day 71). Alternative causes ruled out (no viral serology, no acetaminophen exposure). WHO-UMC assessment: Probable.
Regulatory Report Excerpt (FDA IND Safety Report):
In this interim analysis of Trial XYZ, 42 cases of drug-induced liver injury (DILI) were identified across 5,000 patient-exposures (incidence 0.84%). Disproportionality analysis shows statistically significant signal (ROR 2.8, 95% CI 2.1–3.7). Risk is substantially elevated in patients ≥65 years co-prescribed statins. We recommend amending the protocol to exclude or intensify monitoring in this subgroup.
What's Included
- Signal Detection Framework: Step-by-step methodology for applying pharmacoepidemiology algorithms (ROR, PRR, IC, Bayesian disproportionality) to your adverse event dataset
- Statistical Analysis Templates: Pre-structured prompts for hypothesis formulation, data stratification, sensitivity analysis, and confidence interval interpretation
- Risk Characterization Workbook: Guided analysis of severity, seriousness, mechanism plausibility, dose-response, and temporal relationships for each detected signal
- Causality Assessment Checklist: Interactive tool for organizing case narratives, evaluating WHO-UMC and Naranjo criteria, and documenting causality reasoning
- Regulatory Reporting Templates: Pre-formatted sections for FDA MedWatch, IND safety reports, REMS justification, and EudraVigilance submissions
- Data Validation & QC Forms: Automated checks for duplicate records, missing key fields, outlier narratives, and data integrity issues before analysis
Who It's For
- Pharmacovigilance Specialists
- Clinical Safety Officers and Medical Safety Reviewers
- Regulatory Affairs Professionals preparing safety submissions
- Drug Safety Data Analysts and Epidemiologists
- Clinical Trial Safety Monitors and Data Safety Boards
Best For
- Post-market surveillance signal detection and evaluation
- Periodic safety update reports (PSUR) and risk management planning
- Clinical trial interim safety analyses and safety monitoring
- Risk-benefit characterization for regulatory decision-making
- Expedited adverse event reporting and causality assessment
You might also like
You'll create comprehensive, data-driven workplace wellness programs tailored to your organization's unique needs and constraints. Claude helps you establish clear health goals, design evidence-backed interventions, define success metrics, and build sustainable implementation strategies—complete with stakeholder communication plans and ROI projections. Whether launching a new program or improving an existing one, you get actionable frameworks backed by health research.
Generate regulatory-compliant policy documents, map complex interagency compliance obligations, and prepare comprehensive federal compliance documentation for audits and funding applications. You'll receive standards-aligned policy language, requirement cross-references, and compliance checklists ready for internal review and submission.
This skill generates detailed, customized emergency preparedness plans tailored to your specific location, threats, and organizational needs. It creates actionable response protocols, supply checklists, communication procedures, and evacuation strategies. You get a complete, ready-to-implement emergency framework for households, businesses, schools, or community organizations.
You can create comprehensive, evidence-based workplace wellness programs tailored to your organization's culture and employee needs. The skill helps you develop strategic initiatives with measurable objectives, employee engagement strategies, and ROI metrics that demonstrate program value to leadership. You'll produce complete program designs including needs assessments, activity recommendations, communication plans, and health metrics dashboards.
Process epidemiological surveillance data in real time to detect disease patterns, anomalies, and emerging threats across multiple jurisdictions. Generate executive-ready federal health briefings with key metrics, risk assessments, and recommended coordination actions for CDC, HHS, and state leadership. Streamline inter-agency communication and accelerate decision-making during outbreak response.
You can rapidly design and evaluate evidence-based community health programs that address specific health priorities for your target population. The framework guides you through needs assessment, intervention selection, implementation planning, and evaluation design—helping you create programs that are both effective and equitable. You'll generate detailed implementation roadmaps, resource plans, and sustainability strategies that stakeholders can execute immediately.
You can rapidly structure complex clinical ethical dilemmas using established bioethical frameworks to produce medical-record-ready consultation documentation. This skill maps stakeholder perspectives, identifies competing ethical principles, and delivers defensible recommendations suitable for ethics committees, family meetings, and institutional review—all while ensuring your reasoning withstands legal scrutiny.
This skill helps you investigate emerging health threats across the globe by analyzing outbreak data, identifying patterns, and assessing transmission risks. You can synthesize disease surveillance information, geographic spread analysis, and epidemiological modeling to create comprehensive situation reports that support rapid response decisions.